LNTH
Lantheus Holdings, Inc.
LNTH has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
LNTH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
LNTH's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LNTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $62.87 | -38% |
| Forward | 16x | $101 | — |
| Fair | 24x | $98.08 | -3.1% |
| Current | 25x | $101 | — |
| Expensive | 141x | $579 | +472% |
Historical ranges are pointers, not guarantees.
LNTH's PE is in its fair range at 25x. If earnings grow as analysts expect, today's price would be 16x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over LNTH in the historical PE scenario, which offers more potential upside but is not a forecast.
LNTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
LNTH has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LNTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.35 | +55% |
| Q3 2026 | $4.10 | +73% |
| Q2 2026 | $4.18 | +11% |
| Q1 2026 | $4.19 | +19% |
| Q4 2025 | $3.41 | -22% |
| Q3 2025 | $2.37 | -61% |
| Q2 2025 | $3.75 | -39% |
| Q1 2025 | $3.51 | -46% |
| Q4 2024 | $4.36 | -6.2% |
LNTH's earnings per share have fallen from their peak: $4.10 over the past year, against $6.56 in early 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over LNTH on earnings, with more consistent year-over-year improvement.
LNTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $389.9M | +1.5% |
| Q2 2026 | $388.2M | +2.7% |
| Q1 2026 | $377.3M | +1.2% |
| Q4 2025 | $406.8M | +4% |
| Q3 2025 | $384M | +1.4% |
| Q2 2025 | $378M | -4.1% |
| Q1 2025 | $372.8M | +0.8% |
| Q4 2024 | $391.1M | +10% |
LNTH's revenue grew through 2024 and has held roughly level since: $390M last quarter, up 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.3% | -3.1 points |
| Q2 2026 | 26% | +2.6 points |
| Q1 2026 | 22% | -5.8 points |
| Q4 2025 | 19% | -10 points |
| Q3 2025 | 11% | -24 points |
| Q2 2025 | 23% | -2.8 points |
| Q1 2025 | 27% | -1.4 points |
| Q4 2024 | 29% | -9.7 points |
LNTH's operating margin was 8.3% last quarter, down 3.1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LNTH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LNTH on profitability, with a higher operating margin.
LNTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $99.9M | +5.6% |
| Q2 2026 | $89.9M | +14% |
| Q1 2026 | $121.9M | +23% |
| Q4 2025 | $81.4M | -42% |
| Q3 2025 | $94.7M | -41% |
| Q2 2025 | $79.1M | +7.6% |
| Q1 2025 | $98.8M | -17% |
| Q4 2024 | $141.4M | +26% |
LNTH generated $393M in free cash flow over the past year, down 5.1% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
LNTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +895K shares |
| 1 year | +1.1% | +750K shares |
| 3 years | -2.3% | -1.6M shares |
| 5 years | +1.2% | +790K shares |
| Available history | +71% | +28.3M shares |
LNTH has 68M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $100M |
| Q3 2025 | $100M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LNTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LNTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
LNTH has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LNTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.4 | Neutral |
| Stochastic | 43.2 | Neutral |
LNTH's weekly RSI is 60 (neutral) and its Stochastic is 43 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LNTH PE vs Healthcare Sector
| Metric | LNTH | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 4.4% below |
| PE % | 55 | 29 | 26 pts above |
LNTH is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over LNTH on valuation relative to its sector.
LNTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $100.2 | 1% above |
| 20 week MA | $101.7 | 0.4% below |
| 50 week MA | $88.7 | 14% above |
| 100 week MA | $82.7 | 22% above |
| 200 week MA | $80.9 | 25% above |
LNTH has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LNTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.3 | $14.7 | -27% |
| 2021 | $14.7 | $29.4 | +100% |
| 2022 | $29.4 | $50.6 | +72% |
| 2023 | $50.6 | $62.0 | +22% |
| 2024 | $62.0 | $92.1 | +48% |
| 2025 | $92.1 | $66.7 | -28% |
| 2026 YTD | $66.7 | $101.3 | +52% |
LNTH has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.